Low-Cost Pathology Signals for Risk Stratification in High-Risk Non-Muscle-Invasive Bladder Cancer: A Narrative Review
Cancers · 15.07.2026 · 18 (14) · 2269
DOI: 10.3390/cancers18142269 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 15.07.2026. Verfasst von Núria Sala-González und 7 weiteren Autor:innen. Beteiligte Einrichtung: Catalan Institute of Oncology, Avenida Francia, s/n, 17007 Girona, Spain. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
T1 high-grade (T1HG) urothelial carcinoma of the bladder presents a persistent clinical challenge: despite uniform high-risk classification under EAU guidelines, BCG failure and disease progression rates range from 10% to 40% across published series. Standard clinicopathological variables do not adequately explain this heterogeneity. Three pathological parameters evaluable from routine TURBT specimens—T1 substaging by lamina propria invasion depth, tumour budding at the invasion front, and E-cadherin (CDH1) immunohistochemistry—share a common mechanistic basis in CDH1-driven partial epithelial-to-mesenchymal transition and may refine escalation-oriented risk stratification without requiring additional tissue or molecular testing. We conducted a narrative critical review of PubMed/MEDLINE (January 2000–February 2026; 28 included studies) to evaluate the quantitative evidence for each parameter, with emphasis on reproducibility and BCG-specific outcome data. T1 substaging carries the strongest evidence: pooled progression HR 3.29 (95% CI 2.39–4.51) across 36 studies (n = 6781), with BCG failure of 41% vs. 21% in a centralised BCG-treated registry cohort of 264 patients on multivariable analysis. Tumour budding shows consistent adverse associations in BCG-treated pT1 NMIBC; zero progression was observed in the low-budding subgroup in the only available BCG-specific full-text cohort. CDH1 IHC is directionally supportive but limited by scoring heterogeneity (I2 = 63%). All three parameters are mechanistically coherent and assessable from routine TURBT slides. Prospective validation with pre-specified thresholds and standardised scoring protocols is required before clinical implementation can be recommended.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Catalan Institute of Oncology, Avenida Francia, s/n, 17007 Girona, Spain.
- Girona Biomedical Research Institute, 17007 Girona, Spain.
- Institute of Economic and Legal Research, National Academy of Sciences of Ukraine, 01001 Kyiv, Ukraine.
- Josep Trueta University Hospital, 17007 Girona, Spain.
ORCID-Profile: Sviatoslav Chekhun, Marina Vilaseca, Roger Boix, Berta Bella-Burgos, Josep Comet
Zitieren
APA
Sala-González, N., Chekhun, S., Fina, C., Vilaseca, M., Rossylna, O., Boix, R., Bella-Burgos, B., & Comet, J. (2026). Low-Cost Pathology Signals for Risk Stratification in High-Risk Non-Muscle-Invasive Bladder Cancer: A Narrative Review. Cancers, 18(14), 2269. https://doi.org/10.3390/cancers18142269
Vancouver
Sala-González N, Chekhun S, Fina C, Vilaseca M, Rossylna O, Boix R, et al. Low-Cost Pathology Signals for Risk Stratification in High-Risk Non-Muscle-Invasive Bladder Cancer: A Narrative Review. Cancers. 2026;18(14):2269. doi:10.3390/cancers18142269
BibTeX
@article{SalaGonzlez2026,
author = {Sala-González, Núria and Chekhun, Sviatoslav and Fina, Claudia and Vilaseca, Marina and Rossylna, Olha and Boix, Roger and Bella-Burgos, Berta and Comet, Josep},
title = {Low-Cost Pathology Signals for Risk Stratification in High-Risk Non-Muscle-Invasive Bladder Cancer: A Narrative Review},
journal = {Cancers},
year = {2026},
volume = {18},
number = {14},
pages = {2269},
doi = {10.3390/cancers18142269}
}
EUVIMED